Drug intelligence / Profile preview

ACINIV-P

Development stage
Unknown
Lead developer
Vin Medicament
Modality
Small Molecules
Administration
Oral
01

Overview

ACINIV-P is an oral fixed-dose combination medication developed and marketed by Vin Medicament, primarily indicated for the management of pain and inflammation. The product contains two active pharmaceutical ingredients: aceclofenac and paracetamol (acetaminophen). Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that functions by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of inflammatory prostaglandins. Paracetamol serves as an analgesic and antipyretic agent, providing complementary pain relief through the inhibition of prostaglandin synthesis in the central nervous system. This combination is commonly utilized for the symptomatic treatment of acute painful conditions, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Brand names
ACINIV-P
Other names
Aceclofenac and Paracetamol Tablet
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on ACINIV-P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACINIV-P.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call